WHAT IS NF-B?
Nuclear transcription factor κB (NF-κB) was identified by David Baltimore in 1986 as a factor in the nucleus that binds the promoter of the kappa chain of immunoglobulins in B cells. 1 NF-κB has since been shown to be present in the cytoplasm of every cell type in its inactive state and is conserved in animals all the way from Drosophila to man. Five different mammalian NF-κB family members have been identified and cloned: NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA(p65), RelB, and c-Rel. All family members share a highly conserved Rel homology domain (RHD; ~300 aa) responsible for DNA binding, a dimerization domain, and the ability to interact with IκBs, the intracellular inhibitor for NF-κB. Two different NF-κB activation pathways have been identified, a canonical pathway initiated by NF-κB1 (p50/p105) and a noncanonical pathway initiated by NF-κB2 (p52/p100). Before the NF-κB complex is translocated into the nucleus, NF-κB1 and NF-κB2 are cleaved to the active p50 and p52 subunits, respectively.
In resting cells, NF-κB, consisting of p50 and RelA, is sequestered in the cytoplasm in an inactive form through its association with one of several inhibitory molecules, including IκB-α, IκB-β, IκB-γ, p105, and p100, among which IκB-α is the most abundant. In response to environmental stimuli, including cytokine/chemokines, viral and bacterial pathogens, and stress-inducing agents, inactive NF-κB/IκB complex is activated by phosphorylation on two conserved serine (S) residues within their N-terminal domain of IκB proteins. Phosphorylation of these conserved S residues in response to stimulators leads to the immediate polyubiquitination of IκB proteins by the SCF-β-TrCP complex (FIG. 1) . This modification subsequently targets IκB proteins for rapid degradation by the 26S proteasome.
Activation of the NF-κB signaling cascade results in complete degradation of IκB, allowing the translocation of NF-κB to the nucleus, where it induces transcription. Activated NF-κB binds to specific DNA sequences in target genes, designated as κB-elements, and regulates transcription of over 400 genes involved in immunoregulation, growth regulation, inflammation, carcinogenesis, and apoptosis.
WHAT ACTIVATES NF-B?
Extensive research in the last two decades has shown that a large number of stimuli can activate NF-κB (TABLE 1) . These include bacteria and fungi, bacterial and fungal products, viruses and viral proteins, inflammatory cytokines, parasites, mitogens, physiological stress, physical stress, oxidative stress, environmental and occupational particles, heavy metals, intracellular stresses, viral or bacterial products, UV light, X-rays, gamma radiation, chemotherapeutic agents, carcinogens, cigarette smoke, hydrogen peroxide, colony-stimulating factors, mechanical stress, psychological fear, Th1 cytokines, hypoxia and hyperoxia, chemotherapeutic agents, endotoxins, and tumor promoters. The diversity of the stimuli that can stimulate NF-κB activation suggests that it can be used as a "smoke-detector" or "stress-sensor."
The mechanisms by which these diverse stimuli activate NF-κB are not identical. Perhaps the best understood of these pathways is the tumor necrosis factor (TNF)-induced NF-κB activation pathway (FIG. 1) . The sequential recruitment of TNFR, TRADD, TRAF2, RIP, and IKK leads to TNF-induced NF-κB activation. 2 Recent work from our laboratory has implicated ras, 3 syk, 4 and β-GSK 5 in TNF-induced NF-κB activation. Others have implicated AKT, 6 MEK3, 7 and FAK. 8 TNF-induced NF-κB activation is mediated through the production of reactive oxygen species as SOD 9 and γ-GCS 10 inhibited the activation. Numerous studies have indicated that NF-κB activated by several agents, however, differs from that of TNF. 11, 12 For example, we have shown that NF-κB activated by pervanadate 13, 14 and hydrogen peroxide 12 differs from that activated by TNF. Others have shown that activation of NF-κB by hypoxia, 15 UV, 16 γ-radiation, 17 X-rays, 18 ds RNA, 19 erythropoietin, 20 and hepatitis C virus 21 differs significantly from that activated by TNF. Although activation of NF-κB by most agents requires the activation of IκBα kinase (IKK), activation of NF-κB by UV, X-ray, hypoxia, pervanadate, erythropoietin, H 2 O 2 , and hepatitis C virus (NS5A) has been shown to be IKK-independent.
WHAT GENES ARE REGULATED BY NF-B?
Although initially identified in kappa chain of immunoglobulin, the NF-κB binding sequences have now been identified in over 400 different genes (TABLE 2) . These include inflammatory cytokines (e.g., TNF, IL-1, IL-6, and chemokines), adhesion molecules, inflammatory enzymes (e.g., COX-2, 5-LOX), viral proteins, telomerase, angiogenesis proteins (VEGF), antiapoptotic proteins, and cell cycle-regulatory genes. Besides NF-κB, other transcription factors may modulate the expression of these genes. Microarray analysis has added even more genes to the list of those regulated by NF-κB. 22, 23 
WHICH DISEASES ARE LINKED TO NF-B ACTIVATION?
Constitutive NF-κB activation has now been shown to contribute to the pathogenesis of a large number of diseases (TABLE 3) . These include cancer, diabetes, allergy, rheumatoid arthritis, Crohn's disease, cardiovascular diseases, atherosclerosis, Alzheimer's disease, muscular dystrophy, cardiac hypertrophy, catabolic disorders, hypercholesterolemia, ischemia/reperfusion, angina pectoris, acid-induced lung injury disease, renal disease, gut diseases, skin diseases, incontinentia pigmenti, appendicitis, pancreatitis, peritonitis, sepsis, silica-induced disease, sleep apnea, autoimmunity, lupus erythematosus, psychosocial stress diseases, neuropathological diseases, familial amyloid polyneuropathy, Parkinson's disease, Huntington's disease, and retinal disease. NF-κB activation has also been linked with the human aging process.
A constitutive NF-κB has been detected in most tumor cell types including esophageal cancer, laryngeal cancer, pharyngeal cancer, renal cancer, colon cancer, head and neck squamous carcinoma, lung cancer, bladder cancer, acute myelogenous leukemia, non-Hodgkin's lymphoma, B-cell lymphoma, adult T-cell leukemia, T-cell lymphoma, mantle cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, cervical cancer, nasopharyngeal carcinoma, melanoma, thyroid cancer, liver cancer, breast cancer, ovarian cancer, and prostate cancer. 24, 25 NF-κB can mediate transformation, proliferation, invasion, and angiogenesis of tumor cells. Mutated ras found in several tumors has been shown to activate NF-κB. Chemoresistance and radioresistance have also been linked to NF-κB activation. The p-glycoprotein linked to drug-resistance is also regulated by NF-κB. Similarily, COX-2 overexpressed in most tumors is also regulated by NF-κB. Cyclin D1, overexpressed by most tumors and required for G 1 to S transition, is also regulated by NF-κB. Similarily, VEGF and adhesion molecules required for angiogenesis and metastasis are also regulated by NF-κB.
Many inflammatory genes relevant to the pathogenesis of atherosclerosis are regulated by NF-κB, the activated form of which is present in atherosclerotic plaques. NF-κB has been shown to be activated in atherosclerosis and myocarditis, in association with angina, during transplant rejection, after ischemia/reperfusion, in congestive heart failure, in dilated cardiomyopathy, after ischemic and pharmacological preconditioning, in heat shock, in burn trauma, and in hypertrophy of isolated cardiomyocytes.
Bronchial asthma is one of the most common chronic diseases in modern society and yet, despite the availability of highly effective drugs, there is increasing evidence to suggest that its incidence is increasing. The pathogenesis of asthma involves persistent expression of a broad array of genes, which contain the κB site for NF-κB within their promoters, suggesting that NF-κB plays a pivotal role in the initiation and perpetuation of allergic inflammation.
Several reports suggest that amyloid β peptide can activate NF-κB in neurons, indicating a plausible mechanism by which amyloid may act during the pathogenesis of Alzheimer's disease. Rheumatoid arthritis is a chronic inflammatory disease characterized by persistent joint swelling and progressive destruction of cartilage and bone. NF-κB plays an essential role in transcriptional activation of TNF and IL-1. Together they form a positive regulatory cycle that may amplify and maintain the rheumatoid disease process.
HOW TO INHIBIT NF-B ACTIVATION?
Because of the role of NF-κB in a wide variety of diseases, inhibitors of NF-κB activation are extensively sought (TABLE 4) . Different steps in the NF-κB activation pathway are being targeted to block NF-κB. These include inhibitors of proteosome that mediate IκBα degradation, inhibitors of kinase (IKK), which mediate IκBα phosphorylation, decoy peptides from IκBα, IKK, and p65 proteins. The doublestranded oligodeoxynucleotides (ODNs) that possess consensus NF-κB sequence as transcription factor decoys (TFDs) also have been found to inhibit NF-κB binding to native DNA sites. Examples of proteasome blockers include peptide aldehydes such as ALLnL, LLM, Z-LLnV, and Z-LLL, lactacystine, PS-341, ubiquitin ligase inhibitors, and cyclosporine A. Several cytokines that are produced by Th2 have been found to suppress NF-κB activation. These include IL-4, 26 IL-13, 27 and IL-10. 28 Additionally, endocrine hormones such as HCG, 29 LH, MSH, 30 and GH 31 have been shown to abrogate NF-κB activation. Both IFN-α and IFN-β, which exhibit antiviral, antiproliferative, and immunosuppressive activities, also abolish NF-κB activation. 32 Several phytochemicals from different plants have been identified that can suppress NF-κB activation effectively. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] These include curcumin (turmeric), resveratrol (red grapes), guggulsterone (guggul), ursolic acid (from holy basil), betulinic acid (birch trees), eugenol (cloves), gingerol (ginger), oleandrin (oleander), silymarin (artichoke), emodin (aloe), capsaicin (red chili), anethol (anise), and others. All these blockers of NF-κB have potential in the treatment of a wide variety of diseases. Pharmacological safety, bioavailability, and efficacy in vivo will determine their therapeutic potential in particular diseases.
CONCLUSION
This minireview shows that NF-κB is an important transcription factor that is activated by a wide variety of stimuli, controls the expression of a large number of genes, mediates pathogenesis of various diseases, and can be suppressed by numerous agents. NF-κB activation, however, is required for the proper function of the immune system. Proliferation of T cells and B cells, activation of macrophages, proliferation and survival of dendritic cells, and activation of T cells are dependent on NF-κB activation. Some recent evidence, however, indicates that while NF-κB1 mediates an inflammatory response, NF-κB2 mediates an immune response. 47 This suggests that suppression of the NF-κB1 pathway that controls inflammation may have less effect on the immune system. This remains to be determined. That NF-κB activation has been linked with most diseases is not too surprising considering that as many as 98% of all diseases are proinflammatory. Thus, the thesis that NF-κB is a "smoke-detector" that is activated by cigarette smoke 48 or a "stress-signal" is quite appropriate.
